GeneDx Holdings Corp. (WGS)
NasdaqGS · Price as of · Delayed Quote
- Profitability0/20
Losing money: $-116.4M net income over the last four reported quarters. Revenue over the last four reported quarters was $454.4M, up 19% from $381.1M the year before.
- Insider buying vs selling20/20
Insiders are net buyers: 2 open-market buys worth $11.1M vs 22 sells worth $3.0M across the last 20 Form 4 filings.
- Dilution and offerings6/15
Share count up 3.8% in a year plus 1 offering-related filing. Real dilution. One nuance: offerings raise cash that can fund real growth. The score docks the certain near-term dilution; if the spending pays off, it shows up later in the profitability component.
- Analysts9
- Implied upside+6.2%
- Target range$74.00 to $103.00
- EPS expected$0.07 -85%
- A year ago$0.49
- Revenue expected$123.0M +5.3%
- Estimate range$0.07 to $0.08
WGS closed at $87.51 on Sep 23, up 0.5% since Aug 21. Chart read: price above both the 50-day and 200-day moving averages; the 50-day is below the 200-day (downtrend structure); trading at 40% of the 52-week range ($34.51 to $167.51).
Insider buying and selling at GeneDx Holdings Corp. (WGS)
The most recent Form 4 on record for GeneDx Holdings Corp. (WGS) is September 16, 2026, when Katherine Stueland, CHIEF EXECUTIVE OFFICER, sold $1.0M of stock. Those shares went automatically to cover tax on a vest, so it was not a decision to sell.
| Insider | Action | Value | Date | Type |
|---|---|---|---|---|
| Katherine Stueland · CHIEF EXECUTIVE OFFICER | Sell | $1.0M | September 16, 2026 | No decision |
| Kevin Feeley · CHIEF FINANCIAL OFFICER | Sell | $363,892 | September 16, 2026 | No decision |
| Katherine Stueland · CHIEF EXECUTIVE OFFICER | Sell | $310,932 | September 9, 2026 | No decision |
SEC filings
| Form | Filed | Description |
|---|---|---|
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 18, 2026 | View on EDGAR |
| 4 | September 11, 2026 | View on EDGAR |
| 4 | September 11, 2026 | View on EDGAR |
| 4 | September 3, 2026 | View on EDGAR |
| 144 | September 1, 2026 | View on EDGAR |
| 144 | September 1, 2026 | View on EDGAR |
GeneDx news
Frequently asked questions
When does WGS report earnings?
GeneDx Holdings Corp. (WGS) is scheduled to report quarterly results on October 27, 2026 (estimated). The 8-analyst consensus is $0.07 per share on revenue of $123.0M for the quarter ending September 30, 2026, against $0.49 and $116.7M a year earlier. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for WGS?
9 analysts cover GeneDx Holdings Corp. (WGS). The consensus rating is Strong buy. The average price target is $90.44, in a range of $74.00 to $103.00.
Are insiders buying or selling WGS?
We track Form 4 filings for GeneDx Holdings Corp. (WGS). The activity listed on this page shows 3 qualifying sales. Each row is labelled Routine when the filer declared a pre-arranged 10b5-1 plan, Tax withholding when shares were sold automatically to cover the tax on a vest, or Own call when neither applies.
Where can I see WGS SEC filings?
Recent filings are listed on this page, newest first. The latest is a 4 filed September 18, 2026.